Literature DB >> 12492423

Mitochondrial oxidative metabolism in motor neuron degeneration (mnd) mouse central nervous system.

M Bertamini1, B Marzani, R Guarneri, P Guarneri, P Bigini, T Mennini, D Curti.   

Abstract

The mnd mouse spontaneously develops slowly evolving motoneuron pathology leading to progressive motor impairment. There is strong evidence that a complex interplay between oxidative stress, mitochondria abnormalities and alteration of glutamate neurotransmission plays an important role in the pathogenesis of motor neuron diseases. Therefore, we investigated the presence of mitochondrial dysfunction in frontal, central (comprising the motor area) and occipital regions of the cerebral cortex and in the spinal cord of 35-week-old mnd mice. Lipid peroxide derivatives reacting with thiobarbituric acid (TBARS) were measured in the cervical, thoracic and lumbar spinal cord. In addition biochemical and behavioural analyses were carried out in mnd mice chronically treated with l-carnitine from the 11th to the 34th week of life (mndT mice). Slight but significant alterations of mitochondrial enzyme activities were seen in the mnd cortical regions. The central area was the most affected and both complex I, IV and citrate synthase were decreased with respect to controls. The rate of oxygen consumption (QO2) was markedly decreased in both the upper (cervical + upper portion of the thoracic region) and lower (lumbar + lower portion of the thoracic region) mnd spinal cord. The level of TBARS showed a rostro-caudal trend to increase, being 30% higher in the lumbar tract of mnd mice in comparison with controls. L-carnitine treatment increased the mitochondrial enzyme activities in cortical regions towards control value and was effective in enhancing QO2 and decreasing TBARS levels in the spinal cord of mndT. Behavioural testing showed that L-carnitine significantly delayed the onset of motor behaviour impairment. This beneficial effect was declining at 35 week of age, when the biochemical measurements were performed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12492423     DOI: 10.1046/j.1460-9568.2002.02299.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  8 in total

1.  [NCL in animal models].

Authors:  K Rüther
Journal:  Ophthalmologe       Date:  2010-07       Impact factor: 1.059

2.  A mixed breed dog with neuronal ceroid lipofuscinosis is homozygous for a CLN5 nonsense mutation previously identified in Border Collies and Australian Cattle Dogs.

Authors:  Natalie A Villani; Garrett Bullock; Jennifer R Michaels; Osamu Yamato; Dennis P O'Brien; Tendai Mhlanga-Mutangadura; Gary S Johnson; Martin L Katz
Journal:  Mol Genet Metab       Date:  2019-04-17       Impact factor: 4.797

3.  Lipofuscin accumulation and gene expression in different tissues of mnd mice.

Authors:  Giovanna Traina; Paolo Bigini; Giuseppe Federighi; Leopoldo Sitia; Gabriela Paroni; Fabio Fiordaliso; Monica Salio; Caterina Bendotti; Marcello Brunelli
Journal:  Mol Neurobiol       Date:  2012-03-08       Impact factor: 5.590

4.  Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells.

Authors:  Hai Wei Jin; Sarah J L Flatters; Wen Hua Xiao; Howard L Mulhern; Gary J Bennett
Journal:  Exp Neurol       Date:  2007-11-17       Impact factor: 5.330

5.  Isolated cytochrome c oxidase deficiency in G93A SOD1 mice overexpressing CCS protein.

Authors:  Marjatta Son; Scot C Leary; Nadine Romain; Fabien Pierrel; Dennis R Winge; Ronald G Haller; Jeffrey L Elliott
Journal:  J Biol Chem       Date:  2008-03-11       Impact factor: 5.157

6.  In the rat brain acetyl-L-carnitine treatment modulates the expression of genes involved in neuronal ceroid lipofuscinosis.

Authors:  Giovanna Traina; Rodolfo Bernardi; Enrico Cataldo; Monica Macchi; Mauro Durante; Marcello Brunelli
Journal:  Mol Neurobiol       Date:  2008-08-23       Impact factor: 5.590

Review 7.  Therapeutic landscape for Batten disease: current treatments and future prospects.

Authors:  Tyler B Johnson; Jacob T Cain; Katherine A White; Denia Ramirez-Montealegre; David A Pearce; Jill M Weimer
Journal:  Nat Rev Neurol       Date:  2019-03       Impact factor: 42.937

Review 8.  The wobbler mouse, an ALS animal model.

Authors:  Jakob Maximilian Moser; Paolo Bigini; Thomas Schmitt-John
Journal:  Mol Genet Genomics       Date:  2013-03-29       Impact factor: 3.291

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.